RVX-208 THE FIRST SELECTIVE BROMODOMAIN EXTRA-TERMINAL PROTEIN INHIBITOR BEING DEVELOPED FOR PATIENTS WITH HIGH RESIDUAL RISKS OF CARDIOVASCULAR DISEASE

Authors :: Ewelina Kulikowski
Christopher Halliday
Kenneth Lebioda
Jan Johansson
Norman C.W. Wong
Source :: Journal of the American College of Cardiology. 65:A258
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Genetics
Residual risk
chemistry.chemical_compound
Terminal protein
chemistry
business.industry
Medicine
RVX 208
Disease
Cardiology and Cardiovascular Medicine
Bioinformatics
business
Bromodomain

Tools